QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02509 QYUNS-B

Not Yet Opened 01-13 16:08:13

22.400

+0.220

+0.99%

High23.300	Low22.300	Vol414.80K
Open22.380	D1 Closing22.180	Amplitude4.51%
Mkt Cap5.04B	Tradable Cap5.04B	Total Shares225.00M
T/O9.47M	T/O Rate0.18%	Tradable Shares225.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":22.4,"timestamp":1768291693007,"preClose":22.18,"halted":0,"volume":414800,"delay":0,"floatShares":225000000,"shares":225000000,"eps":-1.710309938408369,"marketStatus":"Not Yet Opened","change":0.22,"latestTime":"01-13 16:08:13","open":22.38,"high":23.3,"low":22.3,"amount":9468238,"amplitude":0.045086,"askPrice":22.5,"askSize":3600,"bidPrice":22.4,"bidSize":12800,"shortable":3,"etf":0,"ttmEps":-0.9658399774073004,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":0,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":22.18,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":1.451923,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"1105363546","title":"QYUNS-B (02509) Repurchases 79,600 Shares for HK$1.75 Million on January 12","url":"https://stock-news.laohu8.com/highlight/detail?id=1105363546","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105363546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:52","pubTimestamp":1768225953,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on January 12, 2026, the company repurchased 79,600 shares at a cost of HK$1.75 million. For more significant Hong Kong stock information and overseas wealth management...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2601809342","title":"Qyuns Therapeutics Repurchases HK$31.16 Million in Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809342","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809342?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:09","pubTimestamp":1767794997,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co. Ltd. has announced a repurchase of a total of 1,575,800 ordinary shares on The Stock Exchange of Hong Kong Limited, with an aggregate amount involved of approximately HK$31.16 million . The repurchased shares represent about 0.69% of the company’s existing total issued shares as of the announcement date. The company stated that the buyback was conducted under a repurchase mandate to reinforce market confidence and enhance investment value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 07, 2026, and is solely responsible for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2fxQ7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1140249954","title":"QYUNS-B (02509) Repurchases 38,800 Shares for HK$778,400 on January 6","url":"https://stock-news.laohu8.com/highlight/detail?id=1140249954","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140249954?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:50","pubTimestamp":1767711014,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on January 6, 2026, the company repurchased 38,800 shares at a cost of HK$778,400. The repurchase price ranged from HK$19.96 to HK$20.10 per share.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2601005865","title":"Qyuns Therapeutics Co., Ltd. (HKG:2509) About To Shift From Loss To Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2601005865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601005865?lang=en_us&edition=fundamental","pubTime":"2026-01-06 08:50","pubTimestamp":1767660635,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. ( HKG:2509 ) is possibly approaching a major achievement in its business, so we would like...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-co-ltd-hkg2509-about-to-shift-from-loss-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-co-ltd-hkg2509-about-to-shift-from-loss-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02509","LENZ","BK1161","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"1110982559","title":"QYUNS-B (02509) Repurchases 25,000 Shares for HK$476,900 on January 2","url":"https://stock-news.laohu8.com/highlight/detail?id=1110982559","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110982559?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:50","pubTimestamp":1767361814,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on January 2, 2025, the company repurchased 25,000 of its own shares at a total cost of HK$476,900. The repurchase price per share ranged from HK$18.75 to HK$19.20.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1174407833","title":"Zhixiang Hong Kong Stock Repurchase Statistics | January 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1174407833","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174407833?lang=en_us&edition=fundamental","pubTime":"2026-01-01 09:13","pubTimestamp":1767230019,"startTime":"0","endTime":"0","summary":"A total of 58 companies conducted share buybacks on December 31, 2025. Among them, TENCENT (00700) executed the largest buyback by value, repurchasing 1.061 million shares for HK$635 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02018","LU0314109678.HKD","LU1568876335.HKD","HK0000320264.USD","LU0898667661.SGD","LU0577902611.USD","HK0000306685.HKD","BK1526","BK1516","02678","09922","BK1535","LU0633140727.USD","LU0417516738.SGD","LU1769817096.USD","LU1504937902.USD","LU2488822045.USD","BK1249","BK1095","LU0831103253.SGD","LU1044876610.USD","LU0047713382.USD","LU0823413587.USD","LU1810669033.SGD","LU1224709979.USD","09857","LU0791591158.USD","LU1366334578.USD","LU0117844026.USD","LU0449515922.USD","LU0862451753.SGD","02598","SG9999001093.SGD","09886","LU1102505929.USD","LU2476274308.USD","LU0501845795.SGD","LU0106959298.USD","LU2097828474.EUR","09896","LU0061477393.USD","LU0979878070.USD","LU0128522744.USD","LU0886674414.USD","SG9999015952.SGD","IE00B031J352.USD","IE00B0169L03.USD","IE0008369823.USD","LU0320764755.SGD","BK1229","LU0254981946.USD","HK0000252160.HKD","LU0868486357.SGD","LU0011963245.USD","IE0034224299.USD","LU2251237306.USD","01458","IE00B543WZ88.USD","BK1504","LU1675838814.USD","LU0163747925.USD","LU0348767384.USD","IE0003851619.USD","BK1610","LU0541502299.USD","LU1226288097.SGD","LU0577902298.EUR","BK1506","IE00B3M56506.USD","LU1720050803.USD","LU0326948709.USD","01672","LU0823041008.USD","SGXZ90724238.SGD","LU2125910849.SGD","LU0244354667.USD","LU1794554557.SGD","LU0791590937.USD","BK1246","BK1167","LU0819123356.HKD","LU0029874905.USD","LU1196710351.USD","LU0289960550.SGD","LU0165289439.USD","SG9999001051.SGD","LU0594300179.USD","SG9999000418.SGD","LU0345776255.USD","SG9999014906.USD","LU0029875118.USD","00909","LU0396098781.USD","LU0259732245.USD","LU0577902538.SGD","BK1191","LU1328277881.USD","LU0572940350.SGD","LU0149534421.HKD","LU1956131251.USD","LU0196878994.USD","LU0819121731.USD","HXXD.SI","LU0823038988.USD","SGXZ51526630.SGD","IE00B0169N27.USD","LU0878005551.USD","LU0589944569.HKD","BK1128","LU1226287792.SGD","LU0605514214.HKD","BK1574","LU0293314216.USD","LU0516423091.SGD","LU0149721374.USD","06831","SG9999018865.SGD","LU0588545490.SGD","LU0650527681.SGD","LU0345769631.USD","LU1807302812.USD","SG9999001689.USD","BK1195","00700","LU0594300419.USD","LU1251922891.USD","LU1642822792.SGD","LU0203345920.USD","HTCD.SI","LU0326950275.SGD","LU1880383440.USD","LU0502904849.HKD","LU2362541273.HKD","LU0531971595.HKD","LU0106259558.USD","BK1608","LU0828237510.HKD","LU2226246903.HKD","IE00B0JY6N72.USD","LU0499858602.USD","01995","LU1785774172.SGD","LU0865486749.SGD","LU0572939691.SGD","SG9999007991.SGD","BK1144","LU1719994722.HKD","LU0211331839.USD","LU2237443549.SGD","BK1104","LU2778985437.USD","LU1718418525.SGD","LU1282649067.USD","SG9999002562.SGD","BK1591","BK1531","LU1981816686.USD","LU0228367735.SGD","LU0516422440.USD","BK1155","BK1209","LU0320764599.SGD","BK1502","SGXZ31699556.SGD","BK1607","LU3063872942.SGD","LU0229945570.USD","LU0588546209.SGD","SG9999003461.SGD","LU0540923850.HKD","LU0588545904.SGD","01651","LU0370786039.SGD","01868","LU2237443465.HKD","LU0449509016.USD","LU2152927971.USD","HK0000252152.HKD","BK1132","LU0181495838.USD","LU2051468812.USD","LU0577902454.USD","LU0708995153.HKD","LU0210527791.USD","GB00BDT5M118.USD","LU0588545730.USD","LU2177674079.SGD","IE00B067MR52.USD","IE0032834883.USD","02219","LU0164880469.USD","LU0049112450.USD","LU1770036033.HKD","IE0008368411.USD","LU0543330566.HKD","SGXZ99366536.SGD","LU1629966141.USD","LU0132412106.USD","BK1131","LU0456842615.SGD","LU0210526637.USD","LU0072913022.USD","09966","LU0786609619.USD","02142","BK1515","BK1523","06078","IE00BQXX3C00.GBP","02419","LU0128522157.USD","SG9999014880.SGD","LU2449936058.SGD","LU2476274720.SGD","SG9999015945.SGD","HK0000320223.HKD","LU2362540622.SGD","BK1518","IE0001KFT4U8.USD","LU0611395673.USD","SG9999006597.SGD","LU1226287529.USD","02886","LU0509642566.USD","LU1733274390.USD","LU2097828557.USD","BK1116","LU0648948544.HKD","LU0096374516.USD","LU0455707207.USD","LU0572944931.SGD","LU0651947912.USD","08017","LU0738912210.USD","LU2106854487.HKD","LU1048596156.SGD","LU0516422366.SGD","LU0918141887.USD","BK1583","IE00B29SXG58.USD","BK1585","LU0164872284.USD","LU0441854154.USD","IE00B031HW06.USD","01810","LU0211977185.USD","LU0651946864.USD","LU2498475776.HKD","SG9999002828.SGD","LU1282651121.HKD","01600","LU0456827905.SGD","LU0985320562.USD","81024","LU1282649141.HKD","LU0210533765.USD","09959","LU0228659784.USD","LU1960683339.HKD","SG9999002463.SGD","BK1215","LU0634319403.HKD","LU0463099449.HKD","LU1152091754.HKD","LU1226288170.HKD","BK1193","LU1515016050.SGD","SGXZ81514606.USD","06098","IE00B5MMRT66.SGD","LU0862451837.USD","BK1100","IE00BQXX3F31.USD","LU1105468828.SGD","02299","LU1282651048.USD","LU0054450605.USD","SG9999015978.USD","LU2237443382.USD","02509","02866","LU2045819591.USD","LU1323998911.USD","02416","BK1587","LU0348783662.USD","LU2460026573.USD","LU1048588211.SGD","HK0000165453.HKD","LU1303224171.USD","IE00BZ08YS42.EUR","LU0348735423.USD","81810","SG9999000459.SGD","LU1868838027.USD","IE00BGV7N243.SGD","BK1160","LU0143863784.USD","LU0543330483.HKD","LU2257852520.SGD","LU0918141705.HKD","IE0032431581.USD","LU0235996351.USD","SG9999006514.SGD","HK0000306701.USD","SG9999013353.USD","LU0417516571.SGD","LU0516423174.USD","BK1221","LU0039217434.USD","BK1258","LU0414403682.SGD","01897","LU0143863198.USD","SG9999015986.USD","LU0264606111.USD","SG9999018857.SGD","LU0175139822.USD","LU2097828631.EUR","BK1521","LU0251144936.SGD","LU1152091168.USD","LU0593848301.USD","00345","LU2237443978.SGD","LU1769817179.HKD","LU1008478684.HKD","LU1211504680.USD","LU1868837565.USD","01024","LU0531970944.HKD","LU0051755006.USD","LU0873338254.USD","LU2293587155.HKD","SG9999014674.SGD","LU0070217475.USD","LU1917777945.USD","LU0456846285.SGD","LU0261947096.USD","BK1109","LU0384037296.USD","LU0856984785.SGD","LU2237443622.USD","LU0823426308.USD","LU0348783233.USD","LU0633140560.USD","LU1868837722.USD","LU0173614495.USD","BK1586","IE0003895053.USD","LU0084288322.USD","BK1613","LU0823040885.USD","BK1500","LU0048597586.USD","LU0348814723.USD","LU2097828805.USD","LU1023057109.AUD","SG9999014914.USD","LU0672654166.SGD","LU0499858438.USD","LU2087589342.USD","LU2237443895.HKD","LU0169518387.USD","BK1237","LU0106252389.USD","LU0214875030.USD","LU0708995583.HKD","LU0203347892.USD","LU1051768304.USD","LU1951186391.HKD","LU2462611646.USD","BK1105","SG9999000327.SGD","LU1224444064.USD","LU2247934214.USD","SG9999004220.SGD","LU1051769294.HKD","BK1575","LU0972618739.USD","SG9999001226.SGD","LU2399975544.HKD","LU1102505762.USD","01516","LU2362541513.USD","LU0052750758.USD","BK1619","00314","SG9999001846.SGD","BK1247","02652","LU0117841782.USD","LU1328615791.USD","LU0882747503.HKD","LU1725190679.HKD","LU0348766576.USD","LU1048484197.HKD","LU0608807946.USD","BK1117","IE00BPRC5H50.USD","XIACY","LU1813983027.USD","LU1282648689.USD","LU0359202008.SGD","LU1733274473.HKD","LU0828237940.HKD","06887","LU0345775950.USD","IE0031814852.USD","BK1589","LU0516422952.EUR","LU1046422090.SGD","LU0054237671.USD","09669","BK1549","IE00B031HY20.USD","IE00BF5LJ272.USD","LU0307460666.USD","LU0890818403.SGD","LU0797268264.HKD","LU1961090484.USD","LU2023250504.SGD","02038","LU0469268626.HKD","LU0488056044.USD","LU0880133367.SGD","LU0327786744.USD","LU0315178854.USD","LU1688375341.USD","LU0359201885.HKD","LU0329678170.USD","BK1517","BK1590","LU1196710864.SGD","LU2242644610.SGD","LU0348788117.USD","LU1226287875.USD","BK1609","BK1142","LU1044874839.SGD","02621","LU1831875114.USD","LU0048580855.USD","LU0188438112.USD","06609","LU0048388663.USD","LU0359201612.USD","LU1655091459.SGD","LU0320764243.SGD","LU0328353924.USD","LU0823039010.USD","LU0107464264.USD","SG9999017495.SGD","02391","LU1044875133.USD","LU0541501648.USD","LU0823397103.USD","LU0127658192.USD","LU1242518931.SGD","BK1508","LU0823426480.USD","LU1814569148.SGD","LU1282649810.SGD","LU1568876251.USD","01274","LU0784639295.USD","LU0348805143.USD","LU1993786604.SGD","LU1196710195.USD","LU1770034418.SGD","LU2125910500.SGD","LU0261950983.USD","LU0642271901.SGD","LU0737861699.HKD","BK1615","BK1233","BK1161","LU2251237488.HKD","LU2317271919.USD","LU0049853897.USD","09878","IE0003795394.USD","LU1226288253.USD","LU1883866441.USD","SG9999001903.USD","BK1618","LU0348827113.USD","LU1439102457.SGD","LU0561508036.HKD","LU0607220059.USD","SG9999014898.SGD","IE00B8HQ1Z84.USD","BK1542","SG9999001069.SGD","06868","IE00BZ08YR35.GBP","LU0164865239.USD","LU0608807433.USD","LU0345769128.USD","LU1439103000.SGD","LU2097828714.EUR","TCHmain","03798","LU0348784397.USD","LU1242518857.USD","LU1808992512.USD","LU0577902371.SGD","LU0828238088.HKD","03650","LU1880383366.USD","LU2265009873.SGD","06100","LU0072462343.USD","LU0348816934.USD","LU0192582467.USD","LU0080751232.USD","LU1734074674.USD","LU0871576103.HKD","LU2133065610.SGD","LU0140636845.USD","LU0269904917.USD","LU0231483743.USD","IE0008368742.USD","LU1316542783.SGD","LU0878004406.USD","06608","BK1124","BK1183","01588","LU0823397285.USD","LU1804176565.USD","02869","LU0675040207.SGD","BK1604","LU2008162690.USD","LU0737861772.HKD","02121","LU0683595622.HKD","IE0009570106.USD","LU0431992006.USD","LU0700851271.USD","LU0067412154.USD","LU1974910355.USD","IE00BZ08YT58.USD","HK0000500386.USD","LU1366334651.USD","LU0417516902.SGD","LU1235295612.USD","LU0821914370.USD","02517","LU2279701549.SGD","BK1566","IE00B8L5B284.USD","BK1253","02586","LU0329678337.USD","LU0823413660.USD","LU2039709279.SGD","LU0043850808.USD","LU0287142896.SGD","IE00B97KM107.HKD","LU0348723411.USD","IE00BQXX3D17.EUR","LU0348825331.USD","LU1188198961.HKD","LU1481107354.HKD"],"gpt_icon":1},{"id":"1131014448","title":"QYUNS-B (02509) Repurchases 160,000 Shares for HK$3.03 Million on December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1131014448","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131014448?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:40","pubTimestamp":1767188412,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on December 31, 2025, it repurchased 160,000 shares at a total cost of HK$3.03 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1127132525","title":"QYUNS-B (02509) Repurchases 92,800 Shares for HK$1.6781 Million on December 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1127132525","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127132525?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:28","pubTimestamp":1767018491,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on December 29, 2025, the company repurchased 92,800 shares at a total cost of HK$1.6781 million.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1145935759","title":"Hong Kong Stocks Movement | QYUNS-B (02509) Rises Over 4% as Bispecific Antibody Drug QX027N Licensed Overseas, Potential Payments Up to $700 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1145935759","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145935759?lang=en_us&edition=fundamental","pubTime":"2025-12-22 10:28","pubTimestamp":1766370485,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) surged over 4%, reaching HK$19.61 by the time of writing, with a trading volume of HK$3.0957 million. The company announced earlier today that on December 19, it entered into a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593172463","title":"Qyuns Therapeutics Sells QX027N Drug License to LE2025 Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2593172463","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593172463?lang=en_us&edition=fundamental","pubTime":"2025-12-22 09:50","pubTimestamp":1766368237,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  sold the global license to its QX027N drug to Windward Bio Group affiliate LE2025 Therapeutics, according to a Hong Kong bourse filing Monday.The license covers all regions except mainland China, Taiwan, Hong Kong, and Macau.Qyuns sold the license for payments totaling up to $700 million, including an upfront payment, an equity interest of Windward Bio, milestone payments, and royalties on the sales of the drug.QX027N is being studied as a treatment for asthma and atopic dermatitis.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","BK4139","BK4007","BK1161","02509"],"gpt_icon":0},{"id":"2593859174","title":"BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2593859174","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593859174?lang=en_us&edition=fundamental","pubTime":"2025-12-22 09:08","pubTimestamp":1766365723,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AGDec 22  - Qyuns Therapeutics Co Ltd 2509.HK:ENTERS LICENSE & COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AGGROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERSLE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERSFurther company coverage: 2509.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ00Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1154764518","title":"QYUNS-B (02509) Signs Licensing and Collaboration Agreement with Windward Bio Subsidiary for Development and Commercialization of QX027N","url":"https://stock-news.laohu8.com/highlight/detail?id=1154764518","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154764518?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:22","pubTimestamp":1766362942,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on December 19, 2025, the company entered into a licensing and collaboration agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2593517917","title":"Qyuns Therapeutics Co Ltd - Le2025 Granted Exclusive Rights for QX027n Development Globally Except From Mainland China, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2593517917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593517917?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:08","pubTimestamp":1766362097,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ00Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593173179","title":"Qyuns Therapeutics - Group to Receive Total of up to $700 Mln Payments, Including Upfront Payment, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2593173179","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593173179?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:08","pubTimestamp":1766362097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ00Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2593017912","title":"Qyuns Therapeutics - Enters License & Collaboration Agreement With Le2025 Therapeutics Ag","url":"https://stock-news.laohu8.com/highlight/detail?id=2593017912","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593017912?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:08","pubTimestamp":1766362097,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ00Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593127179","title":"Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N","url":"https://stock-news.laohu8.com/highlight/detail?id=2593127179","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593127179?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:07","pubTimestamp":1766362076,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5d8lLb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2592603291","title":"Qyuns Therapeutics Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592603291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592603291?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:00","pubTimestamp":1766152803,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co. Ltd. held an extraordinary general meeting on December 19, 2025. Shareholders approved all proposals, including amendments to the articles of association.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL3NGBHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1186184034","title":"QYUNS-B (02509) Rises Over 3% Again as Bispecific Antibody Pipeline Advances Overseas into Clinical Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1186184034","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186184034?lang=en_us&edition=fundamental","pubTime":"2025-12-11 15:34","pubTimestamp":1765438478,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2590372933","title":"Qyuns Secures $5 Million as Australia Clears Phase 1 Trial for QX030N; Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372933","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590372933?lang=en_us&edition=fundamental","pubTime":"2025-12-10 11:34","pubTimestamp":1765337664,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  has received a $5 million milestone payment from partner Caldera Therapeutics after its bispecific antibody QX030N/CLD-423 obtained approval from Australia's Human Research Ethics Committee for a Phase 1 clinical trial, according to a Tuesday Hong Kong bourse filing.Shares of the biotech firm rose nearly 4% in Wednesday morning trade.The study, set to begin in early 2026, will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics across single and multiple IV and subcutaneous dosing in healthy adults, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK1161","02509","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2590340241","title":"BRIEF-Qyuns Therapeutics Says Received Milestone Payment Of $5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340241","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590340241?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:59","pubTimestamp":1765295961,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Says Received Milestone Payment Of $5 Million Dec 9 (Reuters) - Qyuns Therapeutics 2509.HK:RECEIVED A MILESTONE PAYMENT OF US$5 MILLION FROM ITS PARTNER, CALDERA THERAPEUTICSFurther company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":0.1144},{"period":"1month","weight":0.0832},{"period":"3month","weight":-0.1789},{"period":"6month","weight":0.447},{"period":"1year","weight":2.2},{"period":"ytd","weight":0.1928}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Qyuns Therapeutics Co Ltd is a China-based company mainly engaged in biopharmaceuticals. The Company is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The Company's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The Company is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The Company's core products include QX002N and QX005N.","exchange":"SEHK","name":"QYUNS-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"QYUNS-B,02509,QYUNS-B股票,QYUNS-B股票老虎,QYUNS-B股票老虎国际,QYUNS-B行情,QYUNS-B股票行情,QYUNS-B股价,QYUNS-B股市,QYUNS-B股票价格,QYUNS-B股票交易,QYUNS-B股票购买,QYUNS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}